Physician profile
Malcolm S Moore
NPI 1629041322
$2,660.38
in general payments reported to CMS, 2019-2025
17 companies · $629 in 2025
The $629 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $658 · 2020: $195 · 2021: $293 · 2022: $296 · 2023: $234 · 2024: $356 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,218.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $544.22 | 2019-2025 | Unity, Rocklatan, Clareon |
| Allergan, INC. | $404.47 | 2019-2022 | |
| Abbvie INC. | $363.62 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $214.16 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $213.00 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $166.64 | 2023-2025 | Miebo, Xiidra |
| Eyevance Pharmaceuticals LLC | $152.64 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $145.81 | 2019-2021 | |
| Astellas Pharma US INC | $124.66 | 2024 | Izervay |
| Eyepoint US, INC. | $104.83 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $67.95 | 2019-2021 | |
| Dompe US, INC. | $57.07 | 2025 | Oxervate |
| Thea Pharma INC. | $41.14 | 2023 | Iyuzeh |
| Rxsight INC | $17.94 | 2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Shire North American Group INC | $14.31 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $14.06 | 2023 | Interstim |
| Johnson & Johnson Surgical Vision, INC. | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.